- Author:
Byung Woo MIN
1
;
Kwang Soon SONG
;
Ki Cheor BAE
;
Chul Hyun CHO
;
Eun Suck SON
;
Kyung Jae LEE
Author Information
- Publication Type:Review
- Keywords: Osteoporosis; Medication; Hip fractures
- MeSH: Anabolic Agents; Bone Density Conservation Agents; Bone Resorption; Calcium; Diphosphonates; Hip; Hip Fractures*; Humans; Metabolic Diseases; Orthopedics; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporotic Fractures; Parathyroid Hormone; Prevalence; Vitamin D
- From:Hip & Pelvis 2015;27(1):9-16
- CountryRepublic of Korea
- Language:English
- Abstract: Osteoporosis is a metabolic disease that is increasing in prevalence as people live longer. Because the orthopedic surgeon is frequently the first and often the only physician to manage patients with osteoporotic hip fractures, every effort should be made to prevent future fractures. A multidisciplinary approach is essential in treatment of osteoporotic fractures. Basic treatment includes calcium and vitamin D supplementation, fall prevention, hip protection, and balance and exercise programs. Currently available pharmacologic agents are divided into antiresorptive and anabolic groups. Antiresorptive agents such as bisphosphonates limit bone resorption through inhibition of osteoclastic activity. Anabolic agents such as parathyroid hormone promote bone formation.